98%
921
2 minutes
20
Highly transmissible SARS-CoV-2 variants have emerged throughout the COVID-19 pandemic, driving new waves of infections. Genomic surveillance data can provide insights into the virus's evolution and biology. However, delayed and limited regional data can introduce biases in epidemiological models, potentially obscuring transmission patterns. To address this issue, we used a novel, variant-specific back-projection model to estimate a distribution of likely infection times from sample collection times. We combined this approach with epidemiological modeling to estimate selection for increased transmission in a way that accounts for the uncertainty in infection times. Tests in simulations demonstrated that our method can make the inference of selection more reliable. We also applied our approach to SARS-CoV-2 data, where it excelled in smoothing and extending data from geographic regions or times with poor sampling. Overall, our method can aid in the reliable identification of mutations and variants with higher transmission rates.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12236715 | PMC |
http://dx.doi.org/10.1101/2025.06.29.662219 | DOI Listing |
Circ Genom Precis Med
September 2025
Department of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China (J.Z., S.R., L.C., M.C., F.T., B.A., Y.Y., H.L.).
Background: Previous studies have suggested that the associations between ambient air pollution and atherosclerotic cardiovascular diseases (ASCVD) differ by genotype. A genome-wide approach provides a more comprehensive understanding of this relationship on a genomic scale.
Methods: Using data from ≈300 000 UK Biobank participants, we conducted a genome-wide interaction analysis on 10 745 802 variants.
Obesity (Silver Spring)
September 2025
Division of Diabetes and Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Objective: Vertical sleeve gastrectomy (VSG) promotes significant metabolic improvements, though the underlying molecular mechanisms are not fully understood. Emerging evidence suggests that small extracellular vesicles (sEVs) contribute to metabolic improvements post VSG, such as improved fatty liver disease or adipose tissue function; however, it is unclear how different organ-specific sEVs interact with various metabolic parameters. The objective of this study is to establish the role of organ-specific sEVs in the metabolic improvements post VSG.
View Article and Find Full Text PDFJ Cancer Res Clin Oncol
September 2025
Division of Gastroenterology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.
Purpose: Next-generation sequencing (NGS) has revolutionized cancer treatment by enabling comprehensive cancer genomic profiling (CGP) to guide genotype-directed therapies. While several prospective trials have demonstrated varying outcomes with CGP in patients with advanced solid tumors, its clinical utility in colorectal cancer (CRC) remains to be evaluated.
Methods: We conducted a prospective observational study of CGP in our hospital between September 2019 and March 2024.
Nat Biotechnol
September 2025
European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, UK.
The size of microbial sequence databases continues to grow beyond the abilities of existing alignment tools. We introduce LexicMap, a nucleotide sequence alignment tool for efficiently querying moderate-length sequences (>250 bp) such as a gene, plasmid or long read against up to millions of prokaryotic genomes. We construct a small set of probe k-mers, which are selected to efficiently sample the entire database to be indexed such that every 250-bp window of each database genome contains multiple seed k-mers, each with a shared prefix with one of the probes.
View Article and Find Full Text PDFNat Rev Urol
September 2025
Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Low-grade non-muscle invasive bladder cancer is a specific category of bladder cancer with a favourable prognosis; however, its management presents several challenges. The risk of stage progression is very low, but approximately half of patients will experience recurrence within the first 5 years after diagnosis. This high propensity for recurrence, coupled with the threat of progression, mandates ongoing surveillance.
View Article and Find Full Text PDF